In 2022, the members of the Innovative Pharmaceutical Initiative (iF!) recorded at least 159 million kuna* in transferred value to healthcare organizations and healthcare professionals, patient associations, as well as investments in research and development, which enable patients to access the latest therapies and provide physicians with education on new and effective treatment methods.

Of the total amount, the innovative pharmaceutical industry in Croatia invested 40.8 million kuna in research and development last year, which is almost 10.9 million kuna more than in 2021. At least 55.8 million kuna in value was transferred to healthcare professionals, and at least 58.3 million kuna to healthcare organizations, epresenting 36.7 percent of the total transfer. In accordance with regulations ensuring personal data protection, 22.9 percent of physicians voluntarily provided their data for individual disclosure of value transfer information.

As of June 30, iF! members have publicly disclosed data on value transfers to physicians and healthcare organizations, in accordance with the EFPIA Code on Disclosure of Transfers of Value. This marks the eighth consecutive year that the innovative pharmaceutical industry has followed this practice in over 30 countries. The innovative pharmaceutical industry is the first industry in the world to publicly disclose value transfer data, contributing not only to the transparency of public-private sector collaboration but also to a better understanding of the industry’s relationships with healthcare professionals and organizations.

With these funds, the innovative pharmaceutical industry in Croatia has, for example, enabled the implementation of a number of valuable projects by various healthcare organizations through sponsorships and donations, thereby contributing to the improvement of public health in the Republic of Croatia. In addition to the professional development of physicians, the collaboration between the industry and healthcare professionals also involves participation in medical and educational meetings, where physicians provide their expertise, time, and work, for which they receive fair compensation. Research and development refer to the processes of collecting data on the efficacy and safety of specific medicines or medical procedures, and are conducted through clinical studies and collaboration with healthcare organizations, healthcare professionals, and patients. In addition to the transfer of value itself, research and development processes also provide additional value through free medicines, as well as the education of physicians on new and more effective treatment methods. Recognizing the value and contribution of patient associations in the healthcare system, the innovative pharmaceutical industry supported the activities of these associations with a total of nearly 4 million kuna.